



Dear Readers,

At the annual meeting of the EACTS in Vienna, recent clinical data of cell-free aortic and pulmonary valves were presented and discussed in three lectures. After more than 1,000 implantations, orthotopically implanted cell-free allografts have become established as reasonable alternatives for heart valve replacement. We have linked the original articles for you and summarized the key statements synoptically as tables.

With kind regards
Michael Harder

EACTS Annual Meeting 2023, Update

Pediatric AV Replacement



At the EACTS annual meeting in Vienna Dr. Sarikouch reported on the latest results of pediatric aortic valve replacement using decellularized allografts: „Freedom from death was 97.8% and 96.3% at 5 and 10 years, an outstanding result [...]“

Read more here or scan the code on the left:
issuu.com/eacts/docs/eacts_daily_day2_friday_issuu_791f6c52394a4d/13

AV Replacement: ARISE Study



Dr. Sarikouch also reported on the latest results of the prospective, single-arm European trial on decellularized allografts for aortic valve replacement - the ARISE study and ARISE Registry Data: „The five-year results of the prospective multi-center ARISE trial therefore continue to demonstrate DAH as safe for AVR with excellent hemodynamics.“

Read more here or scan the code on the left:
issuu.com/eacts/docs/eacts_daily_day3_saturday_issuu_97b6bf46249089/12

A Graphical Overview of Heart Valve Replacement Options

Aortic Heart Valve Replacement Options And Their Properties Children ≤50kg				
	Mechanical implant	Stentless, stented, TAVI	Allografts (Homografts)	Xellfree® Cell-free Allografts
Source / Material	Metals, Carbon	Biological sources	Tissue donations	Tissue donations
Durability	● Very durable	● Durable	● Less durable ¹	● Durable ²
Hemodynamics	● Acceptable	● Good	● Natural	● Natural
Concomitant Medication	● Severe	● Mild	● Mild ³	● Mild ⁴
Regeneration	● None	● None	● None	● Regenerative Potential ⁵

Aortic Heart Valve Replacement Options And Their Properties Patients >50kg				
	Mechanical implant	Stentless, stented, TAVI	Allografts (Homografts)	Xellfree® Cell-free Allografts
Source / Material	Metals, Carbon	Biological sources	Tissue donations	Tissue donations
Durability	● Very durable	● Durable	● Less durable ¹	● Durable ²
Hemodynamics	● Good	● Good	● Natural	● Natural
Concomitant Medication	● Severe	● Mild	● Mild ³	● Mild ⁴
Regeneration	● None	● None	● None	● Regenerative Potential ⁵



We have compiled the alternatives for aortic (general, pediatric) and pulmonary prosthetic heart valves in tables based on the Publications. They compare source/material, durability, hemodynamics, medication, and regeneration of the following implant types: Mechanical valves, stented and stentless biological valves, allografts (homografts), and xellfree® xell-free allografts. You are invited to download the tables here: <https://cloud.corlife.eu/index.php/s/kNEdzZgzxsboZwg>

	Mechanical implant	Stentless, stented, TAVI	Allografts (Homografts)	Xellfree® Cell-free Allografts
Source / Material	Metals, Carbon	Biological sources	Tissue donations	Tissue donations
Durability	Very durable	Durable	Durable	Very Durable ¹
Hemodynamics	Acceptable	Good	Natural	Natural ¹
Concomitant Medication	Severe	Mild	None/Mild ²	None/Mild ³
Regeneration	None	None	None	Regenerative Potential ⁴

1. Eur J Cardiothorac Surg. 2022 Oct 4;62(5):ezac219. doi: 10.1093/ejcts/ezac219. PMID: 35425983; PMCID: PMC9615428.
 2. Administration of acetylsalicylic acid (e.g., J Heart Valve Dis. 1995 Jul;4(4):392-5)
 3. Administration of acetylsalicylic acid for 6 months (personal communication)
 4. Ann Thorac Surg. 2019 Aug;108(2):581-589. doi: 10.1016/j.athoracsur.2019.02.058. Epub 2019 Mar 28. PMID: 30928547.

The properties of pulmonary heart valve replacement options.

Save the date: Corlife at the DGTHG Annual Meeting 2024

The Corlife Booth at the DGTHG Annual Meeting 2024

From February 17th to 19th we will be happy to welcome you at our booth at the Congress Center Hamburg. Meet us and learn all about developments and applications of Xellfree® Homografts.

dgthg-jahrestagung.de

February 18th, 2024: Wet-lab Cell-free Allografts

In this special workshop, you will get to know cell-free heart valves, cell-free vessels and their surgical application in concrete terms. We plan to set up a total of 6 stations, at each of which a team will perform a heart valve replacement (porzin). The workshop will be introduced by Prof. Lichtenberg (Düsseldorf) and accompanied by colleagues who have already gained experience with cell-free heart valves. The workshop is preferably aimed at teams from one center each, led by an experienced surgeon.